Invest Securities confirms its Buy rating on Transgene shares, with an unchanged target price of 5.4 euros.

Benefiting from extensive media coverage since the weekend, Transgene's share price jumped +22% yesterday (and +40% at its peak) following the presentation of updated data on its personalized head and neck cancer vaccine at the ASCO congress", stresses the analyst.

The results seem "very promising" in terms of the vaccine's therapeutic potential.

Biologically, the results remain consistent with the demonstration of a strong specific immune response induced by the vaccine, and a correlation with the observed clinical benefit", concludes the broker.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.